Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cysteine Hydrochloride

FDA-approved product (injectable, injection), marketed as Cysteine Hydrochloride, Elcys, Nouress.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Cysteine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Liver disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Cysteine Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA9.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli8.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cysteine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cysteine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • NAC Trial for Anosmia

    NCT02481609 · start 2014-07

    Registered record
    Registry ID
    NCT02481609
    Conditions
    Anosmia
    Interventions
    N-acetyl cysteine (NAC)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2014-07
    Completion
    2017-12-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnosmia
    InterventionN-acetyl cysteine (NAC)
    PhaseEarly phase 1
    Registry statusCompleted

  • Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis

    NCT02088216 · start 2014-04-01

    Registered record
    Registry ID
    NCT02088216
    Conditions
    Non-Cystic Fibrosis Bronchiectasis
    Interventions
    N-acetylcysteine; On-demand treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-04-01
    Completion
    2018-03-30
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Cystic Fibrosis Bronchiectasis
    InterventionN-acetylcysteine; On-demand treatment
    PhaseNot applicable
    Registry statusCompleted

  • Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

    NCT02945241 · start 2014-04

    Registered record
    Registry ID
    NCT02945241
    Conditions
    Methicillin-resistant Staphylococcus Aureus; Sepsis; Critical Illness
    Interventions
    Vancomycin; Cystatin C dosing algorithm; Creatine clearance dosing algorithm
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-03
    Enrolment
    399

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-resistant Staphylococcus Aureus; Sepsis; Critical Illness
    InterventionVancomycin; Cystatin C dosing algorithm; Creatine clearance dosing algorithm
    PhasePhase 1
    Registry statusCompleted

  • N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

    NCT01885338 · start 2013-06

    Registered record
    Registry ID
    NCT01885338
    Conditions
    Schizophrenia
    Interventions
    N-acetylcysteine (NAC); Inactive placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    2014-05
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionN-acetylcysteine (NAC); Inactive placebo capsule
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer

    NCT01496157 · start 2012-09-11

    Registered record
    Registry ID
    NCT01496157
    Conditions
    Prostate Cancer
    Interventions
    18F-DCFBC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-09-11
    Completion
    2017-09-17
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F-DCFBC
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bromelin, a Compound Prepared With Ananas Comocus Extract and Honey, for Acute Cough

    NCT01356693 · start 2011-06

    Registered record
    Registry ID
    NCT01356693
    Conditions
    Cough, Acute
    Interventions
    Bromelin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-06
    Completion
    2012-03
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCough, Acute
    InterventionBromelin; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior

    NCT01366859 · start 2011-05

    Registered record
    Registry ID
    NCT01366859
    Conditions
    Autism Spectrum Disorders
    Interventions
    Whey Protein; Rice Protein (Placebo)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2016-10
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorders
    InterventionWhey Protein; Rice Protein (Placebo)
    PhasePhase 2
    Registry statusCompleted

  • Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents

    NCT01111734 · start 2011-03

    Registered record
    Registry ID
    NCT01111734
    Conditions
    Deliberate Self Harm
    Interventions
    N-Acetylcysteine; fMRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2015-05
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeliberate Self Harm
    InterventionN-Acetylcysteine; fMRI
    PhasePhase 1
    Registry statusCompleted

  • N-acetylcysteine (NAC) for Children With Tourette Syndrome

    NCT01172288 · start 2010-07

    Registered record
    Registry ID
    NCT01172288
    Conditions
    Tourettes Syndrome; Tic
    Interventions
    N-Acetylcysteine (NAC); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07
    Completion
    2014-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourettes Syndrome; Tic
    InterventionN-Acetylcysteine (NAC); Placebo
    PhasePhase 2
    Registry statusCompleted

  • N-acetylcysteine in Bulimia Nervosa

    NCT01131572 · start 2010-02

    Registered record
    Registry ID
    NCT01131572
    Conditions
    NAC
    Interventions
    N-acetylcysteine NAC
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2010-02
    Completion
    2012-03
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNAC
    InterventionN-acetylcysteine NAC
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients

    NCT01597765 · start 2009-06

    Registered record
    Registry ID
    NCT01597765
    Conditions
    Thalassemia
    Interventions
    curcuminoids, N-acetylcysteine, deferiprone and vitamin E; Curcuminoids and alpha-tocopherol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThalassemia
    Interventioncurcuminoids, N-acetylcysteine, deferiprone and vitamin E; Curcuminoids and alpha-tocopherol
    PhaseNot applicable
    Registry statusCompleted

  • Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

    NCT00829205 · start 2009-01

    Registered record
    Registry ID
    NCT00829205
    Conditions
    Lymphoma
    Interventions
    filgrastim; rituximab; Se-methyl-seleno-L-cysteine; carboplatin; etoposide; ifosfamide; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2009-01
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; rituximab; Se-methyl-seleno-L-cysteine; carboplatin +4 more
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

    NCT00809094 · start 2008-11

    Registered record
    Registry ID
    NCT00809094
    Conditions
    Cystic Fibrosis
    Interventions
    N-acetylcysteine (NAC); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-02
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionN-acetylcysteine (NAC); Placebo
    PhasePhase 2
    Registry statusCompleted

  • N-acetylcysteine in Alcohol Dependence

    NCT00568087 · start 2007-12

    Registered record
    Registry ID
    NCT00568087
    Conditions
    Alcoholism
    Interventions
    N-acetylcysteine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-12
    Completion
    2009-08
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism
    InterventionN-acetylcysteine; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Diesel Exhaust and Mechanism of Asthma

    NCT01699204 · start 2007-09

    Registered record
    Registry ID
    NCT01699204
    Conditions
    Asthma
    Interventions
    N-acetylcysteine; Diesel exhaust; Filtered air
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2011-10
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionN-acetylcysteine; Diesel exhaust; Filtered air
    PhaseNot applicable
    Registry statusCompleted